News & Events about Castle Biosciences Inc.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Companys medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision Medicine...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022. 2022 was a year of focused investment, and we believe our...
Scotiabank began coverage on shares of Castle Biosciences (NASDAQ:CSTL Get Rating) in a research note released on Wednesday, The Fly reports. The brokerage issued a sector outperform rating and a $54.00 price target on the stock. Separately, Robert W. Baird cut their target price on shares ...
Business Wire
4 months ago
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is presenting data highlighting its portfolio of skin cancer gene expression profile (GEP) tests at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting, being...
Business Wire
4 months ago
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the American Academy of Dermatology validating the performance of DecisionDx-Melanomas proprietary algorithm, i31-ROR...